Maxwell,
Hottod clarified a little while back that the licencing agreement with ACAD doesn't allow them to use NNZ-2591 for Retts in Nth America (and possibly ROW?). In fact doing so would be a breach of the agreement.
From my limited understanding, the approval of Tofinetide / Daybue will make the FDA path easier for NNZ-2591 pending positive trial results (of which there appears to be early indications this is even better than Trof). NEU has learnt much from Trof FDA process so I suspect we'll see quicker approval pathway.
BTW - as at 6th March there were 182k shorted Neu stocks and I'd be surprised if this didn't increased significantly over the last week. there's going to be a few shorters cancelling their chauffeured drivers and hiring electric scooters to get home (if they still own it that is).
Share Price, page-4013
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B | |||
| Open | High | Low | Value | Volume |
| $14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1500 | $16.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.57 | 1717 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |